Safety and Effectiveness of COVID-19 SPUTNIK V Vaccine in Dialysis Patients

Abstract

Given the vulnerability of people with chronic kidney disease to COVID-19, nephrology societies have issued statements calling for prioritization of these patients for vaccination. It is not yet known whether COVID-19 vaccines confer the same high level of protection in patients with kidney disease. The aims of this study were to evaluate the safety measured by the events supposedly attributed to vaccines and the effectiveness evaluated by the presence of antibodies in dialysis patients immunized with the COVID-19 Sputnik V vaccine. Methods: multicenter, observational, and analytical study of a prospective cohort of hemodialysis patients in the Autonomous City of Buenos Aires with a vaccination plan. Patients older than 18 years on dialysis who received both components of the COVID-19 vaccine were included. Results: 491 patients included in the safety analysis. ESAVI with either the first or second component was detected in 186 (37.9% 95% CI 33.6%-42.34%). The effectiveness analysis measures of antibodies against SARS-Cov-2 were performed in 102 patients, 98% had positive IgG against SARS-Cov-2 antibodies 21 days after the second component. In patients with COVID-19 prior to vaccination, antibodies at day 21 after the first component reached almost the highest levels compared to those patients who did not have COVID-19, and the rise between the last measures was lower than patients without COVID-19. Conclusion: Dialysis patients constitute a vulnerable population for SARS-Cov-2 infection, beyond the recommendations that were implemented by dialysis units, full vaccination is a priority and necessary. The Sputnik V vaccine has been shown to be safe and effective in this patient population.

Long-term humoral and cellular responses elicited by Gam-COVID-Vac (Sputnik V) vaccine in hemodialysis patients versus non-renal subjects: a prospective cohort study

“…Data on short-term immunogenicity of the Gam-COVID-Vac vaccine in hemodialysis patients are limited, while long-term data are still lacking. Rosa-Diez et al investigated short-term antibody response after Gam-COVID-Vac immunization and found high seroconversion that reached 98% 21 days after complete vaccination [3]. We observed a similar seroconversion rate (91%), which was almost halved by 6th month, indicating a strong need of boost vaccination by this time.…”

“…Previous studies evaluated the safety and e cacy of Gam-COVID-Vac in general population in both early and long-term period [1,2]. The vaccine immunogenicity in patients receiving maintenance hemodialysis (HD), which are known to be highly vulnerable immunocompromised population, has also been reported previously [3]. However, a lack of knowledge exists concerning long-term Gam-COVID-Vac e cacy in dialysis-dependent patients.…”

Assessment of the humoral response to the homologous Gam-COVID-Vac (Sputnik V) or heterologous Sputnik V/mRNA-1273 (Moderna) vaccination against SARS-CoV-2 in dialysis patients

“…The seroconversion rate of our population under dialysis was similar to that reported by previous studies showing values between 80-98% [15-20-. Rosa-Diez (2021) detected a 98% seroconversion rate in a study including 102 dialysis patients vaccinated with the Sputnik V scheme [16-. On the other hand, studies performed on patients under dialysis conditions immunized with Moderna vaccines have shown seroconversion rates ranging between 95% and 97.9% [15-,18-,21-.…”

Efectividad de la vacuna para SARS-CoV-2 sobre hospitalizaciones por COVID-19 durante la cuarta ola epidémica en Querétaro, México

“…[6] La efectividad de la vacuna ha sido demostrada en diferente grado para la prevención y gravedad del cuadro, entre ellas CoronaVac (Sinovac Biotech), BNT162b2, (Pfizer-BioNTech), mRNA-1273(Moderna), AZD1222 (AstraZeneca), AD5-nCoV (Cansino), Ad26.CoV2S (Jannsen) y Gam-Covid-Vac (Sputnikv), a la par se ha identificado que las condiciones en torno a la población y las dosis de aplicación de la vacuna influyen en la efectividad, considerada esta como la prevención del cuadro o de casos graves que requieren hospitalización, en particular para prevenir hospitalización la efectividad reportada fluctúa entre 79 % y 98 %. [7,8,9,10,11] En este contexto el objetivo del artículo es evaluar el efecto protector de la vacuna para SARS-CoV-2 para hospitalizaciones por COVID-19 durante la cuarta ola epidémica en Querétaro, México.…”